Phase
Condition
Depression
Treatment
Continuous theta burst stimulation (cTBS)
Ketamine Injectable Solution
Positive Affect Training
Clinical Study ID
Ages 15-25 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Phase 1 (all participants)
Current DSM-5 depressive disorder
Severity ≥ 12 on MADRS
Moderate-severe anhedonia (75% of sample) or low anhedonia (25% of sample)
Phase 2 (for participants in TBS and ketamine phase, in addition to above)
• ≥ 1 failed antidepressant trial (for qualification for Phase 2 of study and definition of non-response to TMS in order to be eligible for ketamine) = Treatment for at least 6 weeks with an antidepressant medication reaching recommended dosage for adults for at least 3 weeks of the treatment (e.g., 20 mg fluoxetine)
Exclusion
Exclusion Criteria:
Phase 1 (all participants)
Lifetime psychosis, bipolar disorder, or developmental disorder
Serious, unstable neurological disorder (e.g., seizure disorder)
Brain injury with loss of consciousness
Moderate-severe substance use disorder, past 6 mos.
MRI contraindications (e.g., metal in body)
Phase 2 (for participants in TBS and ketamine phase, in addition to above)
Serious, unstable respiratory or cardiovascular illness
Pre-TBS: Alcohol binge in past week or > 3 drinks/day in past 3 days
Pre-ketamine: use of MAOIs in past 2 weeks
Pregnancy
High blood pressure
Current illicit stimulant use
Lifetime recreational ketamine or PCP use
Study Design
Study Description
Connect with a study center
Loeffler Building
Pittsburgh, Pennsylvania 15213
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.